Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00.Invest with ...
Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...
Seeking Alpha28d
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
The NET market in which Exelixis speculates Cabo could generate "blockbuster" (>$1bn per annum) revenues is also a target for zanzalintinib ("zanza") - but as we can see below, pivotal studies are ...